Why are Pharma Companies Ready to Invest in Real World Evidence?

Aug 1, 2017

Life sciences

Randomized Clinical Trials (RCTs) gather clinical data from a small and limited set of samples. It is increasingly being challenged by the payers and healthcare providers as a method to measure the safety and efficacy of drugs. Since the data gathered from RCTs are obtained in a highly controlled environment over a short period of time, it fails to acknowledge special cases and conditions. The players from wellness ecosystem are looking for a much larger set of real-world data which accounts for all possible variations and special cases and conditions to validate drug safety and efficacy. Real world evidence uses observational data such as patient registries, electronic health records, social and web data, and patients claim data to generate insights and predictive findings on drugs, diseases, and patients.

Real world evidence is a powerful analytical tool which can indicate the effectiveness of the drug under various conditions. Apart from this, there are various other reasons why pharma firms are heavily investing on real world evidence:

Are you ready to empower your business with analytics? Request a FREE proposal to learn how Quantzig’s analytics solutions can help you transform your business.

Cost Savings and Increased Returns

The best practice medical research methodology of RCT is very expensive and time-consuming. Apart from the cost of carrying out the trial multiple legal compliance issues needs to be addressed. Real world evidence can be delivered at a relatively low cost as it eliminates dodgy results of clinical drug trials which increase the R&D costs.

Support Value Demonstration and Safety Claims

Real world evidence can support regulatory approvals on the safety and efficacy of new drugs and medical devices by augmenting RCT data. It provides real world data on the effectiveness of the new drugs and supports the safety claims regarding FDA’s accelerated approval programs. Also, it reassures physicians on the safety and efficacy of the drugs which can lead to increased uptake of the product.

To gain more insights on the trends in real world evidence analytics, speak to our experts.

Reduction in Time to Market

Real world evidence analytics can provide accurate data which can be validated so that pharma companies can secure reimbursement for the drug. Traditionally, pharma companies tend to play defensive and watch out for the consequence of a drug before rolling out in the market. But, accelerated approval process with real world evidence can bring the drugs to market much quicker resulting in revenue realization in advance.

Related Articles:

Ready to Harness Game-Changing Insights?

Request a free solution pilot to know how we can help you derive intelligent, actionable insights from complex, unstructured data with minimum effort to drive competitive readiness, market excellence, and success.

Recent Blogs

Supply Chain Analytics and its Importance for Businesses

Supply Chain Analytics and its Importance for Businesses

Supply chains generate massive amounts of structured and unstructured data, which, when used efficiently, can enable organizations to gain intelligent, actionable insights. Traditional supply chains, that do not make use of data analytics are siloed and slow-moving,...

read more
Four Metrics in the Telecom Industry to Make Smart Decisions

Four Metrics in the Telecom Industry to Make Smart Decisions

What you can expect from the Telecom Analytics Metrics Article IntroductionTelecom Analytics Metrics Highlights of the Telecom Analytics Metrics Article S NoTelecom Analytics Metrics1.Average Revenue Per User (ARPU)2.Minutes of Usage (MOU)3.Churn Rate4.Subscriber...

read more

Industries

Our advanced analytics expertise spans across industries, sectors, and functions, which enables us to deliver robust, agile solutions to all our clients. These are our core competencies, formed through years of experience.

Insights

Our free resources shed light on our extensive expertise and equip you with information to accelerate decision-making, growth, and innovation.

Talk to us
Talk to us